SHARE
Enlarge / The unproven vaccine candidate has been dubbed "Sputnik V"Aurich Lawson / Getty Images

Russian President Vladimir Putin announced Tuesday that Russia is the first country in the world to grant regulatory approval for a COVID-19 vaccine—dubbed “Sputnik V.”

Putin claimed that one of his own daughters has already received a dose of the vaccine, according to reports from Moscow—though he didnt note which daughter. Russian officials pledged to vaccinate millions within the month, starting with healthcare workers and teachers.

Little is known about Sputnik V, which was developed by researchers at the Gamaleya Institute in Moscow. There is no public data on the vaccine, let alone any published, peer-reviewed scientific studies. Public registration of two small clinical trials notes that Sputnik V uses a viral-vector-based design, but they suggest that it has only been tested in a small number of people. The trials, which began less than two months ago, each enrolled 38 healthy volunteers and have an estimated study completion date of August 15.

The World Health Organization, which tracks international COVID-19 vaccine development efforts, lists Sputnik V as being only in the first of three main clinical trial phases. Generally, Phase I clinical trials for vaccines are small—typically only involving dozens of people—and only assess the safety of the candidate. Phase II trials may involve hundreds of people and look further at safety, dosing, and the immune responses that the vaccine triggers, which may hint at the vaccines possible efficacy. Then there is the Phase III trial, which often involves tens of thousands of people and looks at whether the vaccine protects against infection and disease.

It appears that Russia has skipped Phase III—and possibly has not finished Phase II yet.

In a meeting Tuesday, Putin reportedly said that “of course, what counts most is for us to be able to ensure the unconditional safety of the use of this vaccine and its efficiency in the future. I hope that this will be accomplished.”

Dubious design

There may already be reason to doubt the efficacy of Sputnik V. The vaccine is a viral vector-based vaccine. That is, it uses two harmless adenoviruses to deliver parts of the pandemic coronavirus, SARS-CoV-2, to the immune system. This is a common design, but it's one that has a notable pitfall.

Adenoviruses in humans tend to cause mild infections and common colds. For vaccine delivery, theyre usually engineered so they cant replicate, making them even more harmless. Russian researchers further tinkered with the adenovirus so that it carries the genetic coding for SARS-CoV-2s spike protein. The aptly named spike protein is a barb-like structure that juts out from the viral particle and is critical for infection. The spike protein grabs ahold of a receptor on human cells called ACE2 (angiotensin-converting enzyme 2), which allows the virus to get into the cell, take over, and churn out more viral particles. By delivering the spike protein in the adenovirus, researchers are hoping it trains antibodies and defensive immune cells to seek and destroy SARS-CoV-2 by recognizing the spike proteins.

Several other high-profile COVID-19 vaccine candidates use this basic strategy—but theres a catch. Sputnik uses adenoviruses that commonly infect humans. In people who have already been infected with these common viruses, the vaccine may not prompt a strong immune response against the spike protein if immune cells recognize the adenovirus packaging and respond to it instead.

Crazy Russians

This appeared to be the case for a Chinese vaccine candidate developed in part by biotechnology company CanSino. The companys human adenovirus-based vaccine prompted weaker immune responses to SARS-CoV-2 in people with existing adenovirus immune responses. And in some populations, up to 80 percent of people have had exposure to the human adenovirus the researchers used in the vaccine. Nevertheless, China is pushing ahead with the vaccine, which is now moving to Phase III trials and is Read More – Source

[contf] [contfnew]

arstechnica

[contfnewc] [contfnewc]

LEAVE A REPLY

Please enter your comment!
Please enter your name here